Sign in

DROR on OTC

Dror Ortho-Design, Inc.

Dror Ortho-Design, Inc. is an American dental equipment and supplies company based in Jerusalem.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Sonendo (United States), SmileDirectClub or Envista Holdings Corporation, or pick any stock.

  • TickerDROR on OTC1
  • IndustryDental Equipment & Supplies1
  • HeadquartersWashington, Pennsylvania1
  • Incorporated inDE2
  • Business address480 Johnson Road, Suite 200, Washington, Pa 153012
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Pictured: Base control unit, containing micro-pump and controls, attached to the smart aligner. The smart aligner is composed of an outer mouthpiece structure, which is shaped based on the final position of the teeth for a perfect smile. Behind the outer mouthpiece structure is a micro balloon that is attached to the base control unit with a fine and flexible microtube. The balloon delivers pulsating air by inflating and deflating. Behind the balloon is the “push structure,” which provides the balloon with a surface to push against as it gently moves the teeth.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-6631.7%Operating margin4
-6639.8%Net margin4
156.8%Revenue growth, 20214
-7.5%Return on equity5

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Other costs92¢$2.4K
  • Interest8¢$207

Out of $2.6K in revenue.4 The company lost money this year.

Financial statements

Revenue64$2.6K in 2021+157% since 2020
0$1.0K$2.0K$3.0K2020: $1.0K$1.0K20202021: $2.6K$2.6K2021+157%
Operating income764-$170.3K in 2021+27% since 2019
-$200.0K-$150.0K-$100.0K-$50.0K02019: -$133.9K-$133.9K20192020: -$167.7K-$167.7K2020+25%2021: -$170.3K-$170.3K2021+2%
Net income764-$170.5K in 2021+27% since 2019
-$200.0K-$150.0K-$100.0K-$50.0K02019: -$134.2K-$134.2K20192020: -$168.0K-$168.0K2020+25%2021: -$170.5K-$170.5K2021+2%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development$815.9K$1.5M
General and administrative expenses$1.4M$1.4M
Share-based compensation$39.2K$2.2M
Total Operating Expenses$2.2M$5.2M
Loss from operations-$2.2M-$5.2M
Financial expense, net-$41.5K-$32.0K
Change in fair value of derivative$29.4K
Registration Rights Agreement expense-$520.0K
Convertible promissory note discount amortization-$309.9K
Total other expenses, net-$321.9K-$552.0K
Loss before provision for income taxes-$2.5M-$5.8M
Net loss-$2.5M-$5.8M
Net loss per common share, Basic (in Dollars per share)$0.00-$0.01
Net loss per common share, Diluted (in Dollars per share)$0.00-$0.01
Weighted-average common shares outstanding, Basic (in Shares)957.0M shares672.5M shares
Weighted-average common shares outstanding, Diluted (in Shares)957.0M shares672.5M shares

Compare Dror Ortho-Design, Inc. with another company

Corporate structure

Dror Ortho-Design, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Dror Ortho-Design, Inc.

  • Dror Ortho-Design, Inc. Washington, Pennsylvania

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Dror Ortho-Design, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Furniture and fixtures$36.4K10 Dec 31, 2025$35.4K10 Dec 31, 2024+2.7%
Accumulated depreciation$16.2K10 Dec 31, 2025$11.3K10 Dec 31, 2024+43.9%
Property and equipment, net$20.2K10 Dec 31, 2025$24.1K10 Dec 31, 2024−16.5%

Properties, in its own words

We lease commercial space that has a gross area of approximately 860 square feet at Shatner 3, Jerusalem, Israel. This space is used as an office, production, testing, adjustment, and preparation center for the shipment of orthodontic appliances. This space is approved for our activities by the certification body MEDCERT. MEDCERT is one of the largest German Notified Bodies that provides ISO and CE certification. The inspection of our facility is carried out on an annual basis by an auditor on behalf of MEDCERT and includes an inspection of all activities and their adaptation to ISO 13485:2016 certification. We have successfully passed our most recent annual inspection in April 2023.

We also lease a small, approximately 130-square-foot storage facility at Hartom 7, Jerusalem, Israel.

Item 2 of the 10-K filed Feb 27, 2026.3

Leadership

Who has led Dror Ortho-Design, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Thomas G. Anderson2006–2011
  2. Orin Hirschman2020
  3. Eliyahu Haddad2023–2024

Chief financial officer

  1. Ran Israeli2026–now
2010201520202025
Board members and other officers (16)

Former names

  • NOVINT TECHNOLOGIES INCMar 5, 2004 to Aug 14, 20232

Timeline

  1. Sep 25, 20268-K Shareholder vote27
  2. Aug 19, 20268-K Entered a material agreement; Unregistered sale of shares28
  3. May 1, 20268-K Entered a material agreement; Unregistered sale of shares29
  4. Mar 4, 20268-K Entered a material agreement; Unregistered sale of shares30
  5. Jan 6, 20268-K Entered a material agreement; Unregistered sale of shares31
  6. Dec 8, 20258-K Entered a material agreement; Unregistered sale of shares32
  7. Jul 23, 20258-K Entered a material agreement; Unregistered sale of shares33
  8. Jun 25, 20258-K Shareholder vote34
  9. Jun 18, 20258-K Entered a material agreement; Unregistered sale of shares35
  10. Jun 10, 20258-K Other events36
  11. Jun 5, 20258-K Entered a material agreement; Unregistered sale of shares37
  12. Jan 4, 20248-K Change to shareholders' rights; Executive or director change; Bylaws or fiscal year changed38
  13. Sep 27, 2023New chief executive Eliyahu Haddad becomes CEO11
  14. May 26, 2020New chief executive Orin Hirschman becomes CEO12
  15. Feb 9, 2006New chief executive Thomas G. Anderson becomes CEO13

Filings

89 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 19 major events, 13 insider forms, 8 large holders, 1 private raises, 27 other. The latest 20:

  1. Sep 25, 20268-K CURRENT REPORT EDGAR
  2. Sep 16, 2026S-1/A AMENDMENT NO. 4 TO FORM S-1 EDGAR
  3. Sep 9, 2026DEF 14A PROXY STATEMENT EDGAR
  4. Aug 28, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
  5. Aug 19, 20268-K CURRENT REPORT EDGAR
  6. Jul 30, 202610-Q QUARTERLY REPORT EDGAR
  7. Jun 5, 20263 EDGAR
  8. May 13, 202610-Q QUARTERLY REPORT EDGAR
  9. May 1, 20268-K CURRENT REPORT EDGAR
  10. Apr 1, 2026S-1/A AMENDMENT NO. 3 TO FORM S-1 EDGAR
  11. Mar 4, 20268-K CURRENT REPORT EDGAR
  12. Feb 27, 202610-K ANNUAL REPORT EDGAR
  13. Feb 3, 2026S-1/A AMENDMENT NO. 2 TO FORM S-1 EDGAR
  14. Jan 29, 2026SCHEDULE 13G/A EDGAR
  15. Jan 6, 20268-K CURRENT REPORT EDGAR
  16. Dec 8, 20258-K CURRENT REPORT EDGAR
  17. Nov 18, 202510-Q QUARTERLY REPORT EDGAR
  18. Nov 17, 2025NT 10-Q NOTIFICATION OF LATE FILING EDGAR
  19. Aug 14, 202510-Q QUARTERLY REPORT EDGAR
  20. Jul 23, 20258-K CURRENT REPORT EDGAR

The 89 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Aug 14, 2023Raised $62.2 million in a private offering of equity Form D: 39 investors so far Form D

SEC filer profile

How Dror Ortho-Design, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDror Ortho-Design, Inc.1
  • CIK0001282980
  • Employer ID (EIN)85-04617783
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)3843 Dental Equipment & Supplies1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address480 Johnson Road, Suite 200, Washington, PA 153011
  • Phone724-206-15001
  • Shares outstanding976,997,116 as of Jul 30, 20269
  • Public float$19.4M as of Jun 30, 20253
  • AuditorBarzily and Co., Jerusalem, Israel PCAOB ID 2015; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMar 5, 20041
  • Filings247 in all: 8-K (32), 10-Q (26), 3 (19), 4 (14), CORRESP (11), NT 10-Q (11), SB-2/A (11), SC 13G/A (10)1
    All 47 form types

    424B3 (9), UPLOAD (9), 10-K (8), SC 13G (8), REGDEX (7), 10QSB (6), S-1/A (6), DEF 14A (5), REGDEX/A (4), SC 13D (4), 10KSB (3), D (3), EFFECT (3), NT 10-K (3), PRE 14A (3), 10-12G (2), 10-K/A (2), 8-K/A (2), POS AM (2), RW (2), S-1 (2), SB-2 (2), SCHEDULE 13G/A (2), 10-12G/A (1), 10KSB/A (1), 15-12G (1), 4/A (1), 8-A12G (1), ARS (1), DEFR14A (1), DRS (1), PRE 14C (1), PRER14A (1), PRER14C (1), S-8 (1), SC 13D/A (1), SCHEDULE 13D/A (1), SCHEDULE 13G (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (10-K) Feb 27, 2026
    Quarterly report (10-Q) Jul 30, 2026
    Proxy statement (DEF 14A) Sep 9, 2026
    Latest 8-K (8-K) Sep 25, 2026

Risk factors and legal proceedings

The risks Dror Ortho-Design, Inc. names in Item 1A of its 10-K filed Feb 27, 2026: 64 risks under these headings, as written.3

  • Risks Related to Our Capital Requirements and Financing
  • Our financial statements have been prepared on a going concern basis; we must raise additional capital to fund our operations in order to continue as a going concern.
  • Macroeconomic and External Risks
  • We conduct our operations in Israel. Conditions in Israel, including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israel’s war against them, may affect our operations.
  • Our operations and financial performance depend on global and regional economic conditions. Inflation, fluctuations in currency exchange rates, changes in consumer confidence and demand, and weakness in general economic conditions and threats, or actual recessions, could materially affect our business, results of operations, and financial condition.
  • Our business could be impacted by major public health issues, including future pandemics.
  • Our business could be impacted by political events, trade and other international disputes, war, and terrorism, including the military conflict between Russia and Ukraine.
  • Our operations may be impacted by natural disasters, which may become more frequent or severe as a result of climate change and may adversely impact our business and operating results as well as those of our potential customers and suppliers.
  • Business and Industry Risks
  • We are in the development stage, are not generating revenues and have no operating history as a manufacturer and distributor of orthodontic medical devices or platforms for consumer use.
  • Our products and technologies may not be accepted by the intended commercial consumers of our products, which could harm our future financial performance.
  • We expect continued operating losses and cannot be certain of our future profitability.
The other 55 risks
  • We may be unable to raise additional capital, which could harm our ability to compete.
  • We will depend on the acceptance of teledentistry and a demand for correcting tooth alignment.
  • Our net revenues will depend primarily on our Platform and any decline in sales or average selling price of our Platform may adversely affect net revenues, gross margin and net income.
  • We will face competition from large internationally established aligner companies whose products have been widely accepted.
  • Our business model depends on being able to reach consumers to raise brand awareness and encourage downloading our smartphone application, which may not prove successful or may become less effective or more costly to maintain in the long term.
  • Future sales of our Platform may depend on our customers’ ability to obtain reimbursement from third-party payors, such as insurance carriers.
  • Our growth and future success may depend on our ability to enhance our Platform or to develop, obtain regulatory clearance for, successfully introduce, and achieve market acceptance of new products and services.
  • Operational Risks
  • Business disruptions could seriously harm our financial condition.
  • We are subject to operating risks, including excess or constrained capacity and operational inefficiencies, which could adversely affect our results of operations.
  • Our products and information technology systems are critical to our business. Issues with product development or enhancements, IT system integration, implementation, updates and upgrades could disrupt our operations and have a material impact on our business and operating results.
  • Our success depends on key executive personnel, vendors, and relationships with key dental professionals and organizations.
  • Legal, Regulatory and Compliance Risks
  • Complying with regulations enforced by FDA and other regulatory authorities is expensive and time consuming, and failure to comply could result in substantial penalties.
  • We may not receive the necessary authorizations to market any future new products, and any failure to timely do so may adversely affect our ability to grow our business.
  • Certain modifications to our products may require new 510(k) clearance or other marketing authorizations.
  • Our products must be manufactured in accordance with federal, state, and international regulations, and we could be forced to recall our products or terminate production and/or face other regulatory enforcement actions if we fail to comply with these regulations.
  • Ongoing changes in healthcare regulation could negatively affect our revenues, business and financial condition.
  • Our products may cause or contribute to adverse medical events that we are required to report to FDA and other governmental authorities, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, results of operations, and financial condition. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of FDA or another governmental authority, could have a negative impact on us.
  • Changes in internet regulations could adversely affect our business.
  • Disruptions at the FDA, other agencies or notified bodies caused by funding shortages or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved, or commercialized in a timely manner, or at all, which could negatively impact our business.
  • The misuse or off-label use of our Platform may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies, particularly if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.
  • Laws and Regulations Governing Healthcare, including Health Information Privacy and Security Laws
  • We are subject to certain federal, state, and foreign fraud and abuse laws, health information privacy and security laws, and transparency laws, which, if violated, could subject us to substantial penalties. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business.
  • Since our Platform will utilize cloud-based information systems and the exchange of information between patents and doctors, we will be subject to numerous U.S. federal and state laws and regulations related to the privacy and security of personally identifiable information, including health information.
  • Our business could be adversely affected by professional and legal challenges to our business model or by new state actions restricting our ability to provide our products and services in certain states.
  • Security breaches, data breaches, cyber attacks, other cybersecurity incidents or the failure to comply with privacy, security and data protection laws could materially impact our operations, patient care could suffer, we could be liable for damages, and our business, operations and reputation could be harmed.
  • Our business will expose us to potential liability for the quality and safety of our products and services, how we advertise and market those products and services and how and to whom we sell them, and we may incur substantial expenses or be found liable for substantial damages or penalties if we are subject to claims or litigation.
  • Increased focus on current and anticipated environmental, social and governance (“ESG”) laws and increased scrutiny of our ESG policies and practices may materially increase our costs, expose us to potential liability, adversely impact our reputation, employee retention, willingness of potential customers and suppliers to do business with us and willingness of investors to invest in us.
  • We are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our actual or perceived failure to comply with such obligations could harm our business, and changes in such regulations or laws could require us to modify our products, marketing or advertising efforts.
  • We will be subject to a number of risks related to the credit card and debit card payments we plan to accept.
  • We face risks related to our future international sales, including the need to obtain necessary foreign regulatory clearance or approvals.
  • Intellectual Property Risks
  • Our success depends in part on our proprietary technology, and if we are unable to successfully enforce our intellectual property rights, our competitive position may be harmed.
  • If we infringe or violate the patents or proprietary rights of other parties or are subject to an intellectual property infringement or misappropriation claim, our ability to grow our business may be severely limited.
  • Our failure to secure trademark registrations could adversely affect our ability to market our products and operate our business.
  • We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
  • Obtaining and maintaining patent protection depends on compliance with various procedures and other requirements, and our patent protection could be reduced or eliminated in case of non-compliance with these requirements.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
  • Risks Related Our Securities
  • The relative lack of U.S. public company experience of our management team may put us at a competitive disadvantage.
  • Our Common Stock is not listed on any stock exchange and there is a limited market for shares of our Common Stock. Even if a market for our Common Stock develops, our Common Stock could be subject to wide fluctuations.
  • As a result of the Share Exchange, we became a company that is subject to the reporting requirements of federal securities laws, which can be expensive and may divert resources from other projects, thus impairing our ability to grow.
  • Public company compliance may make it more difficult for us to attract and retain officers and directors.
  • Because we became public by means of a reverse merger, we may not be able to attract the attention of major brokerage firms.
  • Our stock price may be volatile.
  • Our securities are restricted securities with limited transferability.
  • We are subject to penny stock rules which will make the shares of our Common Stock more difficult to sell.
  • FINRA sales practice requirements may also limit a stockholder’s ability to buy and sell our stock.
  • We do not anticipate paying any cash dividends.
  • Our shares of Common Stock are very thinly traded, and the price may not reflect our value and there can be no assurance that there will be an active market for our shares of Common Stock in the future.
  • We may need additional financing which may not be available on acceptable terms, which may in turn dilute your investment in us.
  • Our board of directors can authorize the issuance of preferred stock, which could diminish the rights of holders of our Common Stock, and make a change of control of us more difficult even if it might benefit our stockholders.
  • Anti-takeover provisions under Delaware corporate law may make it difficult for our stockholders to replace or remove our board of directors and could deter or delay third parties from acquiring our Company, which may be beneficial to our stockholders.
  • Future sales of significant amounts of our Common Stock may depress our stock price.
  • Financial, Tax and Accounting Risks
  • Changes in, or interpretations of, accounting rules and regulations, could result in unfavorable accounting charges.
  • We have identified a material weakness in our internal control over financial reporting, and if we are unable to remediate the material weakness, or if we experience additional material weaknesses in the future, our business may be harmed.
  • Our effective tax rate may vary significantly from period to period.
  • New tax laws and practices, changes to existing tax laws and practices, or disputes regarding the positions we take regarding tax laws, could negatively affect our provision for income taxes as well as our ongoing operations.

Legal proceedings

From time to time, we may be involved in litigation that arises through the normal course of business. As of the date of this filing, we are not a party to any material litigation nor are we aware of any such threatened or pending litigation.

There are no proceedings in which any of our directors, officers or affiliates or any registered or beneficial stockholders is an adverse party or has a material interest adverse to our interest.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41